Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.